{"name":"UroGen Pharma Ltd.","slug":"urogen-pharma-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"UGN-104","genericName":"UGN-104","slug":"ugn-104","indication":"Non-muscle invasive bladder cancer","status":"phase_3"},{"name":"UGN-102","genericName":"UGN-102","slug":"ugn-102","indication":"Upper tract urothelial carcinoma","status":"phase_3"},{"name":"UGN-103","genericName":"UGN-103","slug":"ugn-103","indication":"Non-muscle invasive bladder cancer","status":"phase_3"}]}],"pipeline":[{"name":"UGN-104","genericName":"UGN-104","slug":"ugn-104","phase":"phase_3","mechanism":"UGN-104 is a synthetic, small molecule that acts as a prodrug, which is converted into its active metabolite in the bladder.","indications":["Non-muscle invasive bladder cancer"],"catalyst":""},{"name":"UGN-102","genericName":"UGN-102","slug":"ugn-102","phase":"phase_3","mechanism":"UGN-102 is a mitomycin C-based intravesical therapy that delivers chemotherapy directly to the bladder urothelium to treat non-muscle invasive bladder cancer.","indications":["Upper tract urothelial carcinoma","Non-muscle invasive bladder cancer"],"catalyst":""},{"name":"UGN-103","genericName":"UGN-103","slug":"ugn-103","phase":"phase_3","mechanism":"UGN-103 is a synthetic, small molecule that targets the urothelial cancer cells.","indications":["Non-muscle invasive bladder cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxOREZzYXJ4V3VUcnh4RmhPcERpMFpyOXZwN1ZSRkloS3owU2prRUJfVG12UzBxTlNxcHFnRS1sTG5NT2FBR213UzhWZF82YnY1ZEljdi04a0l4V3RFOHJia1RXaGZyOXdNVlRZamVlSENqTERZZ01hOWVFM0paMmxmWE11MGdPTkVXM3F5LUVkM21WUEtYbnJTY1QxYm9FUGhnUjZtUkFXMVVWaXBJZmhQT1lHUlQxa0ZvVFI3ckRyeE1GbHpYOC03NXotYnVJZ2Y2YVlVSFU2aWRVeWVHLVJhc3FXTnY4Nlk?oc=5","date":"2026-04-08","type":"pipeline","source":"marketscreener.com","summary":"UroGen Pharma Ltd. Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment Of Patients with Low-Grade Upper Tract Urothelial Cancer - marketscreener.com","headline":"UroGen Pharma Ltd. Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment Of Patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE5lYkpwdGpmQUVNRjhOeF9qYkVTdnhSUFhzdFc5d0pWVFBpOWd5dWNKRnNiMnhraE5haXQwbHFrQXNLZEYxSjJUeEVQZERLVVhCajFGeU1BNXgtWkJhTU1fWTRIbnd5QQ?oc=5","date":"2026-04-04","type":"pipeline","source":"Stock Titan","summary":"URGN SEC Filings - Urogen Pharma 10-K, 10-Q, 8-K Forms - Stock Titan","headline":"URGN SEC Filings - Urogen Pharma 10-K, 10-Q, 8-K Forms","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPMFVqZU1zYVdIVmg0ZkFMTl9adjBLYUlKYkRQRnBTSEZXYmljTjlJRUdKQkE0WEh2ZjQ1QnRCUUhQMnNVdUJXZmJxbERtanJJYkZGRTdzWlgyckRfYkFoZWkwSHVwaWhWeXZ2VjB5Q2ZSZGtiZlJ0Z0JBQ0VqUWFpLTYtWkxzUkN5QnBoUk1YUnVnWV85cnUtWm1IWQ?oc=5","date":"2026-04-02","type":"pipeline","source":"The Chronicle-Journal","summary":"UroGen Pharma Ltd. - Ordinary Shares (NQ: URGN - The Chronicle-Journal","headline":"UroGen Pharma Ltd. - Ordinary Shares (NQ: URGN - The Chronicle","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxOZ296TUQtYURQTHNBZ3dGN3VLbW1NeVc4M0RwejU4UnVvRGd1ZW1YREk3bnc4WU1TY284d19RZldPaE9jRXdQZEhnSERZR2VfSV9nalRhbmZrQWFSTDdRZmhYbnhsYnR4Mzh5NFI2ZVlnUWRQeUdIN2R0djRKLVZ4c25wdU1FSlMzSkl3UkF0Y2JmZWFxT1FtcFNHd0lfdlZpSVhaZXdTdTR6V3IwT08xZ0hlRVk3aFJrVVU1QXdPN1RKUDhpVGVEVHN3ZnIzNjg2OFU3Vjl3?oc=5","date":"2026-03-31","type":"pipeline","source":"MarketBeat","summary":"Hennion & Walsh Asset Management Inc. Boosts Stock Position in Urogen Pharma $URGN - MarketBeat","headline":"Hennion & Walsh Asset Management Inc. Boosts Stock Position in Urogen Pharma $URGN","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxQbXZuUVpBRFNFNmk5a25fWFFST0hHUFlxX2V5MkZ3NEVlMEJjRER5NXd3MHMxNnppNjBOVmdnRXZQUnZaaENjSTdkRnRodGVDdmtpQTFVWmQ4UXdEN3VtOXE4dlp0dVFSNkF0VTdzRElRQ1pkb1J5UV84S0NEdjFOaWVaVWFGbzh2dHFpQzRZNXVJekFTb2ZUWWFaOEpQcU9aNFVQdi1NMTlUWlpfYl82di0yNVRBeWQxLXpUSDZwdEVPOFY1aERmLVVWLTgxVjBFTWNKOXNBLV9yMDIzT3BRN3hB?oc=5","date":"2026-03-06","type":"pipeline","source":"GlobeNewswire","summary":"UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire","headline":"UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxPZHFfX2FtblNoV3NzTkljNHo1SGQ5dW1qQ2hpSnB5cW5NQWtLN2swSE9URXdOY1BjTFZ0RThEMzVaY0MxZHRDSENJNmROV2c3anc3VTQ5TGF6aGZ0bDlsV1BFcE90SW9Jc1ZtdC1JcUlHR1NmNkhXRkFDakI3THJIRzNFWFFqN0VPMTg2UF8wR1p1UFBsUEtJaEVpMlc0dWNkLVBSNHFHa2dGbzFjSmZRVTRyRGpkRVFGNHN0NUw5YkVtVlctZlQwUDBBVzRyQQ?oc=5","date":"2026-03-02","type":"pipeline","source":"Akin","summary":"Akin, an Elite Global Law Firm - Akin","headline":"Akin, an Elite Global Law Firm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxQaGlTRnp3MjhVQ1JQNVF2d1hyWGhGOHFHTjhsMWllbXBZRi02akEySXRLb3NwVnNmOWNuMkE3N05pMTJaZWJMLWZRU1JEcnpzaU84UlpETmJSTHZ3RTRUTnRTLUV6MTJPOHhJdVQ3bjRIS1Vhd0g4Zm1sMzkwTkczSllnc05jN0NCWUhDX1dLV05PODktdXVUbHJCQUsxYWNsUzBUTThvcGE5NExYMTJqYTRkSGlteWVCRk5LMzZtc294Y0RadV9Gd3dqNFZiZlU3?oc=5","date":"2026-03-02","type":"earnings","source":"Investing.com","summary":"Earnings call transcript: UroGen Pharma Q4 2025 misses EPS and revenue forecasts - Investing.com","headline":"Earnings call transcript: UroGen Pharma Q4 2025 misses EPS and revenue forecasts","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxNeGxLaTlhS3NleTBYTXhhS3lTWEtNQVJCTlpQdHZlYmhXRkZaaDJCbG5jMmEzRDlwUE4tQnR4UmRMS2xlY0lpS2NhenB6V1NObDI1M0JFeGFEZVlhc2N2YnpHUjNzYmhZZWRKZjR4NjRQT0loTkp3VlJRZERlRHRlXzJKWmliU21rYjI1WXdMUzdBeE4zTy1QQWZjekRENkVHNVdRdDNVUHFmTW8tclVmQ0pDWTVyN3l0My1NYU5Ya0F4dkFuMDhzeXhzc19TU2M?oc=5","date":"2026-02-23","type":"earnings","source":"Quiver Quantitative","summary":"UroGen Pharma Ltd. to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026 - Quiver Quantitative","headline":"UroGen Pharma Ltd. to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-09","type":"pipeline","source":"simplywall.st","summary":"Market Sentiment Around Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN) - simplywall.st","headline":"Market Sentiment Around Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQQkFtZVVKVk1oVmJKVjhMbkFrOGRVVVVpcHBlQ2hZLXdMTkhQZGxoRHEyZWs4NFFhLXdkX1JaSU9ESlpXcnhfU2xtSUFwcTJpN0xETGFwYnVnZ0tKbk5ZSldSa3dmUGx3enZfUnZkUWFfY1BEUWQ2RTVvNGVMYV84a3JpY0haSW1QUjN0SHRJTTk4RTQ?oc=5","date":"2026-02-04","type":"pipeline","source":"Yahoo Finance","summary":"UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit - Yahoo Finance","headline":"UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQWFdmYVl2N1B6TGlZN3dNMnAwbEZudGdCQy04c3BDSkpyMU1mbW1fUlBLZl9xbXlnWmFBOWR4QU9pZEg4cHZLTzAwbDJkclJXQURFWGNSWW8wVGdrTFBJVlpsREVyUVJIRFU2cXpTRUt3VlktaDJiSU1ZdnJYWnNXWg?oc=5","date":"2025-12-31","type":"pipeline","source":"Yahoo Finance","summary":"Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN) Expected To Breakeven In The Medium-Term - Yahoo Finance","headline":"Loss-Making UroGen Pharma Ltd. (NASDAQ:URGN) Expected To Breakeven In The Medium-Term","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQYjRrT25PRVUwdFFJWmZHMktMYVUxSG9sN0FCalNFRF9mbWh5TnlvSFhsX1JSaWpKbWZYNm4xZ29BNWMwUXhvVjRmdDRvanFvckNaUURxT25HS2xJV3pEWHJqX1EyeTZlSWdIdGp5b3dWRnR6UGFOdUx1RkJ5RHNOM2lVQXU0eC1WazR6NVFsNEp3dlpUbDVkVHRZaUk2Ym1jUUloR3VSS25tTWxfZ0tqeWJn?oc=5","date":"2025-11-25","type":"pipeline","source":"Seeking Alpha","summary":"UroGen Pharma: Strong Potential As Zusduri Commercialization Accelerates - Seeking Alpha","headline":"UroGen Pharma: Strong Potential As Zusduri Commercialization Accelerates","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}